Study characteristics:
|
Ref13
|
Ref14
|
Refs 15,16
|
Ref17
|
Ref18
|
Ref19
|
Ref20
|
Ref21
|
Ref22
|
Ref 23
|
Patients
|
Osteoarthritis | x | | | x | | x | x | x | | |
Rheumatoid arthritis | | x | x | | x | | | | x | x |
Treatment
|
Misoprostol | x | x | x | x | x | x | x | x | x | x |
Placebo | x | x | x | x | x | x | x | x | x | x |
H2 receptor antagonist | | | | | x | | | | | |
Misoprostol/diclofenac | | | | | x | | | | | |
Study design
|
Meta-analysis | | | x | x | | | | | | x |
RCT | x | | | x | | x | x | x | x | x |
Cohort study | | | | | | x | | | | |
Population survey | | | | | | | | x | | |
Selected literature | | x | | | x | | | | | |
Costs
|
3-150 Direct costs: |
Admission to hospital | x | x | x | x | x | x | x | x | x | x |
Ambulatory care | x | x | x | x | | x | x | x | x | x |
Drug treatment (prophylaxis) | x | x | x | x | x | x | x | x | x | x |
Treatment of adverse events | | | | x | | | | | x | |
Doctor's visit | x | x | | | x | | | x | | |
3-150
Indirect costs
| | | | | | | x | | | |
Primary outcome |
Cost/lives saved | x | x | | | | | | | | |
Cost/adverse events averted | | | | x | | | | | x | |
Cost/QALY3-151
| | | x | | | | | | | |
Cost/patient | | | | | x | | x | x | | x |
Cost only | | | | | | x | | | | |
Misoprostol compared with placebo: |
Cost effective | x | | | | a3-150
| | x | x | | |
Conditionally cost effective | | x | | x | | x | | | x | |
Cost only | | | | | | | | | | x |
Costly | | | x | | | | | | | |